文献速递主动脉疾病

现代背景下血管内主动脉修复的财务可行性

Financial viability of endovascular aortic repair in the modern era.
PubMed 文献 · J Vasc Surg · 2020-05-27

该单中心回顾性研究纳入2014年1月至2018年12月择期EVAR患者188例,比较2015年CMS的DRG编码变更前后的医院财务指标。结果显示每次住院的医院利润(CTI)从3615美元增至8062美元(+4447美元,+123%),净收入增加2054美元(+7.1%),总直接成本下降2012美元(-7.9%)。DRG报销增加是主要驱动因素,但降低植入物和手术室成本以及改善编码准确性也同等重要。

要点

  • CMS 2015年DRG编码变更后,择期EVAR的医院利润(CTI)增加4447美元(+123%)。
  • 净收入每次住院增加2054美元(+7.1%),总直接成本下降2012美元(-7.9%)。
  • 植入物成本下降1259美元(-7.4%),手术室人力成本下降477美元(-17.0%)。

核心结论

  • 研究期间择期EVAR的医院CTI显著改善,CMS 2015年DRG编码变更带来的报销增加是主要驱动因素。
  • 降低植入物和手术室成本以及改善编码与文档准确性对财务回报也有同等重要的影响。

研究设计与样本

  • 单中心回顾性研究,纳入2014年1月至2018年12月择期EVAR患者188例。
  • 按2015年DRG变更前后分组:组1(变更前,DRG 237/238)67例(36%),组2(变更后,DRG 268/269)121例(64%)。
  • 总直接成本包括植入物成本、手术室人力、食宿和其他供应成本;净收入反映真实付款方组合值,未基于标准Medicare费率外推。
  • 医院利润定义为间接贡献(CTI),即净收入减去总直接成本。

主要发现

  • CTI(利润)从组1的3615美元增至组2的8062美元,增加4447美元(+123%)。
  • 每次住院净收入增加2054美元(+7.1%)。
  • 组1中较高报销DRG编码237应用于5/67例(7.5%),组2中DRG编码268应用于19/121例(15.1%)。
  • 每次住院总直接成本下降2012美元(-7.9%)。
  • 植入物成本从组1平均每次住院16914美元降至组2平均15655美元(-1259美元,-7.4%);手术室人力成本从2838美元降至2361美元(-477美元,-17.0%)。

临床怎么用

  • 择期EVAR的财务可行性可通过优化DRG编码和文档准确性来改善。
  • 降低植入物和手术室成本对提高医院利润有重要贡献。

局限性

  • 单中心回顾性研究,结果可能受机构特异性因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the current era of cost containment, the financial impact of high-cost procedures such as endovascular aneurysm repair (EVAR) remains an area of intensive interest. Previous reports suggested slim to negative operating margins with EVAR, prompting widespread initiatives to reduce cost and to improve reimbursement. In 2015, the Centers for Medicare and Medicaid Services (CMS) announced the reclassification of EVAR to more specific diagnosis-related group (DRG) coding and predicted an overall increase in hospital reimbursement. The potential impact of this change has not been described. METHODS: Patients undergoing elective EVAR at a single institution between January 2014 and December 2018 were identified retrospectively, then stratified by date. Group 1 patients underwent EVAR before DRG change in 2015 and were classified with DRG 237/238, major cardiovascular procedure. Group 2 patients underwent EVAR after the change and were classified as DRG 268/269, aortic/heart assist procedures. The total direct cost included implant cost, operating room (OR) labor, room and board, and other supply costs. Net revenue reflected real payer mix values without extrapolation based on standard Medicare rates. Hospital profit was defined as the contribution to indirect (CTI), subtracting total direct cost from net revenue. RESULTS: A total of 188 encounters were included, 67 (36%) in group 1 and 121 (64%) in group 2. Medicare patients composed 84% of group 1 and 81% of group 2. CTI (profit) increased by $4447 (+123%) from $3615 in group 1 to $8062 in group 2. Net revenue per encounter increased by $2054 (+7.1%). In group 1, the higher reimbursement DRG code 237 was applied in 5 of 67 (7.5%) patients, whereas DRG code 268 was assigned in 19 of 121 (15.1%) patients in group 2. Total direct cost per encounter decreased by $2012 (-7.9%). This decrease in cost was driven by a reduction in implant cost, from a mean $16,914 per encounter in group 1 to a mean $15,655 in group 2 (-$1259 or -7.4% per encounter) and by a decrease in OR labor cost, $2838 in group 1 to $2361 in group 2 (-$477 or -17.0% per encounter). CONCLUSIONS: A significant improvement in hospital CTI was observed for elective EVAR during the course of the study. The increased DRG reimbursement after the Centers for Medicare and Medicaid Services coding changes in 2015 was a major driver of this salutary change. Notably, efforts to reduce implant and OR cost as well as to improve coding and documentation accuracy over time had an equally important impact on financial return.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Brinster CJ, Escousse GT, Bazan HA, et al. Financial viability of endovascular aortic repair in the modern era. J Vasc Surg. 2020. PMID: 32473346. doi:10.1016/j.jvs.2020.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。